BioTime (NYSEAMERICAN:BTX) Now Covered by Analysts at Lake Street Capital

Lake Street Capital started coverage on shares of BioTime (NYSEAMERICAN:BTX) in a research note issued to investors on Friday, February 2nd, MarketBeat Ratings reports. The firm issued a buy rating and a $8.00 price objective on the biotechnology company’s stock.

A number of other equities research analysts have also commented on BTX. Zacks Investment Research upgraded BioTime from a hold rating to a buy rating and set a $2.75 target price on the stock in a research report on Wednesday, November 15th. BidaskClub lowered BioTime from a sell rating to a strong sell rating in a research report on Wednesday, October 18th. Three investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $5.81.

BioTime (NYSEAMERICAN:BTX) opened at $2.60 on Friday. BioTime has a fifty-two week low of $2.10 and a fifty-two week high of $3.62. The stock has a market cap of $323.63, a PE ratio of 6.05 and a beta of 1.95.

A number of hedge funds and other institutional investors have recently bought and sold shares of BTX. Schwab Charles Investment Management Inc. raised its stake in BioTime by 51.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 163,100 shares of the biotechnology company’s stock valued at $514,000 after purchasing an additional 55,600 shares during the last quarter. Rhumbline Advisers increased its stake in shares of BioTime by 23.3% in the 2nd quarter. Rhumbline Advisers now owns 75,201 shares of the biotechnology company’s stock worth $237,000 after acquiring an additional 14,205 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of BioTime by 6.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 474,858 shares of the biotechnology company’s stock worth $1,496,000 after acquiring an additional 29,827 shares during the last quarter. Alliancebernstein L.P. increased its stake in shares of BioTime by 52.7% in the 2nd quarter. Alliancebernstein L.P. now owns 83,700 shares of the biotechnology company’s stock worth $264,000 after acquiring an additional 28,900 shares during the last quarter. Finally, Teachers Advisors LLC increased its stake in shares of BioTime by 8.7% in the 2nd quarter. Teachers Advisors LLC now owns 130,670 shares of the biotechnology company’s stock worth $412,000 after acquiring an additional 10,501 shares during the last quarter.

TRADEMARK VIOLATION WARNING: “BioTime (NYSEAMERICAN:BTX) Now Covered by Analysts at Lake Street Capital” was published by Week Herald and is owned by of Week Herald. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://weekherald.com/2018/02/20/biotime-btx-earns-buy-rating-from-analysts-at-lake-street-capital.html.

BioTime Company Profile

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply